MedPath

A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder

Phase 2
Completed
Conditions
Major Depressive Disorder
Registration Number
NCT00073203
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Brief Summary

The purpose of this research study is to determine the effectiveness of 2 target doses of R228060 in comparison with placebo during 6 weeks of treatment in moderately to severely depressed adult subjects with major depressive disorder.

Approximately 488 subjects will be involved in the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
488
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

JJ PRD Research Center

πŸ‡ΊπŸ‡Έ

Titusville, New Jersey, United States

JJ PRD Research Center
πŸ‡ΊπŸ‡ΈTitusville, New Jersey, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.